Historical clx News Stories
Clorox Cuts FY26 Guidance; GOJO Strains Margins!!.
Clorox lowered FY26 adjusted EPS guidance and warned of significant margin pressure driven by weaker demand, higher energy and freight costs, ERP-related disruptions, and the short-term integration effects of its GOJO (Purell) acquisition. Shares fell sharply after the guidance cut. While GOJO expands Clorox’s hygiene portfolio, it creates near-term margin dilution and inventory step-up costs; management expects synergies to materialize in later years. Key near-term risks include oil-driven cost headwinds, ERP stabilization, and recovery in underperforming segments such as litter and food.
Clorox Cuts Guidance; Shares Fall to 52-Week Lows!
Clorox reported mixed results: a modest EPS beat but a lowered full-year guidance that sent CLX shares sharply lower. Rising input costs, integration headwinds and sector-wide pricing pressures are weighing on near-term profit expectations.
Clorox Shock: GOJO Deal, Q2 Hits, Stock Signals #1
Clorox closed its GOJO acquisition while navigating ERP disruption and softer Q2 sales; the stock swung on execution risks, mixed guidance, and defensive sector flows.
Clorox Eyes Growth After GOJO Close; Apr 30 Call
Clorox (CLX) closed its $2.25B GOJO acquisition and set April 30 for Q3 FY2026 results—events that materially shift near-term investor focus toward integration execution, margin recovery, and dividend sustainability.
Clorox After GOJO: Earnings, Yield & Valuation Q3!
Clorox completed the GOJO (Purell) acquisition and will report Q3 FY2026 results on April 30. The deal, recent heavy trading, a near-5% dividend yield, and below-median valuation create a mix of near-term integration risk and longer-term upside potential for CLX investors.
Clorox Closes GOJO Deal; Earnings, Dividends React
Clorox completed its acquisition of GOJO (Purell) while reporting mixed Q2 results. Investors responded with elevated trading, a modest stock pullback, and continued interest in Clorox’s attractive dividend. Integration risks, margin volatility, and shifting institutional ownership now shape near-term expectations for CLX.
Clorox Faces Margin Squeeze; GOJO Deal May Rescue.
Clorox (CLX) is under pressure from margin compression and shifting consumer choices, prompting analyst downgrades. Recent company updates — an ERP rollout completion, participation at Citi’s consumer conference, and progress on the GOJO (Purell) acquisition with ~$50M expected synergies — outline a path to mid‑term recovery. Key investor watch items are synergy execution, margin inflection, and planned deleveraging from ~3.6× to ~2.5× by 2027.
Clorox Faces Downgrade; $2.25B Debt for GOJO
Clorox was downgraded by a major analyst amid margin pressure and weakening demand while recent SEC filings show $2.25 billion in new borrowing to finance the GOJO acquisition. The move raises near-term leverage and execution risks even as hygiene exposure could boost long-term growth.
Clorox Faces Downgrade, Debt Strain After GOJO Buy
Clorox (CLX) saw a near‑term analyst downgrade tied to margin compression and softer consumer demand while filings reveal a $2.25B GOJO acquisition financed with a $1B revolver and $1.25B term loan—raising leverage and integration scrutiny.
Clorox Downgraded: Sell -CLX Faces Margin Pressure
A major Wall Street firm downgraded Clorox (CLX) to Sell on March 2, 2026, citing margin erosion from elevated input costs and shifting consumer behavior toward private-labels. Broader CPG pressures — notably packaging and tariff-driven cost increases — compound near-term headwinds for the company.
Clorox Q2 Results, ERP Finish and GOJO Takeover
Clorox reported modest revenue decline and an EPS drop in Q2 FY2026 while completing a major ERP rollout and moving to acquire GOJO. The mix of operational milestones, a regulatory fine, and reaffirmed full-year guidance drove muted stock reactions and leaves margin recovery and integration execution as key near-term catalysts.
Clorox Q2 Results: Margin Pressure Stable Dividend
Clorox’s Q2 FY2026 report showed modest sales decline, margin compression and lower EPS, but management reaffirmed full-year guidance. Near-term performance hinges on ERP-related inventory shifts and the pending GOJO acquisition while steady dividend and strong YTD stock returns keep investor interest.
Clorox Rally: GOJO Deal, Q2 Miss and Outlook Ahead
Clorox shares climbed after a four‑day rally as Q2 results showed an EPS miss but stable sales, a $2.25B GOJO acquisition, ERP normalization and modest fines. Investors watch integration, margin recovery and cash flow.
Clorox Q2 Results, GOJO Deal Drive CLX Rally Redux
Clorox’s Q2 FY2026 showed modest revenue and EPS declines amid ERP-related shipment timing, while the $2.25B GOJO (Purell) acquisition and steady cash flow helped spur a multiday stock rally. Investors are watching ERP normalization, synergy capture, and integration timing as near-term catalysts for CLX.